EGFR and neoplasm: We have also focused on the development of bispecific antibodies for cancer treatment21,22 and have reported the marked in vitro and in vivo anti-tumor activity of hEx3-Db, a humanized bispecific Db targeting epidermal growth factor receptor (EGFR) and CD323.